Načítá se...
Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells
Patients with HER-2/neu-expressing breast cancer remain at risk for relapse following standard therapy. Vaccines targeting HER-2/neu to prevent relapse are in various phases of clinical testing. Many vaccines incorporate the HER-2/neu HLA-A2 binding peptide p369–377 (KIFGSLAFL), since it has been sh...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3529812/ https://ncbi.nlm.nih.gov/pubmed/23180824 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1201264 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|